PF-Atlas › Clinical Trials › NCT06861413
A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
VX-828 · Phase 1
Registry ID
NCT06861413
Phase
Phase 1
Status
Completed
Drug / intervention
VX-828
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2025-04-01
Enrollment
68
Locations
1
About this trial
The purpose of this study is to evaluate the relative bioavailability of a VX-828 tablet formulation compared to a suspension and evaluate its safety and tolerability.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06861413 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.